Skip to main content
. Author manuscript; available in PMC: 2023 May 30.
Published in final edited form as: J Thorac Cardiovasc Surg. 2022 Jan 23;164(5):1327–1337. doi: 10.1016/j.jtcvs.2022.01.019

TABLE 2.

Perioperative outcomes of NEOSTAR and ICON patients

Variable NEOSTAR
 ICON
 P value
Neoadjuvant nivolumab (n = 21) Neoadjuvant Nivolumab with ipilimumab (n = 16) Neoadjuvant chemotherapy (n = 34) Upfront resection (n = 107)
R0 resection     21 (100)     16 (100)     29 (85)    100 (94)   .16
30-Day mortality       0       0    1 (3)     1 (1)   .64
90-Day mortality    1 (5)       0    1 (3)     2 (2)   .60
EBL, mL   150 (50-1000)   100 (50-400)   250 (10-2750)    150 (20-2100)   .02
Operative time, minutes   158 (71-315)   142 (95-278)   174 (87-508)    156 (74-506)   .16
Length of stay, d    4 (1-18)    5 (1-15)    6 (3-11)     5 (2-37)   .04
Complications    8 (38)    5 (31)     16 (47)   58 (54)   .24
 Pulmonary    4 (19)    5 (31)     11 (32)   31 (29)   .75
 Cardiac    4 (19)       0    4 (12)   20 (19)   .22
 Gastrointestinal    3 (14)       0       0     3 (3)   .07
 Genitourinary       0       0       0     9 (8)   .15
 Neurological       0    1 (6)       0     2 (2)   .45
 Wound    1 (5)    0 (0)    1 (3)     6 (6) 1.00
pRBC transfusion       0       0    3 (9)     7 (7)   .53

Data are n(%) or median (range). NEOSTAR, Nivolumab With or Without Ipilimumab in Treating Patients With Previously Untreated Stage I-IIIA Non–Small Cell Lung Cancer; ICON, The Immunogenomic Profiling of NSCLC; EBL, estimated blood loss; pRBC, packed red blood cells.